| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/16/2013 | US20130122075 Encapsulated transfer factor compositions and methods of use |
| 05/16/2013 | US20130122064 Ophthalmic Depot Formulations for Periocular or Suconjunctival Administration |
| 05/16/2013 | US20130122062 Polymeric compositions containing ir-emitting/absorbing additives and shaped articles comprised thereof |
| 05/16/2013 | US20130122061 Delayed Release Tablet With Defined Core Geometry |
| 05/16/2013 | US20130122060 Using bucky paper as a therapeutic aid in medical applications |
| 05/16/2013 | US20130122056 Ratiometric Combinatorial Drug Delivery |
| 05/16/2013 | US20130122053 Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| 05/16/2013 | US20130122051 Methods of preparing progesterone pharmaceutical compositions |
| 05/16/2013 | US20130122050 Compositions and methods for treating diabetes using lisofylline analogs and islet neogenesis associated peptide |
| 05/16/2013 | US20130122042 Benzonapthyridine compositions and uses thereof |
| 05/16/2013 | US20130122021 B7-h3 in cancer |
| 05/16/2013 | US20130122018 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 05/16/2013 | US20130122017 Osteoprotegerin in Neuroprotection |
| 05/16/2013 | US20130122008 Anti-IL 1- ß Antibody Combination Therapy |
| 05/16/2013 | US20130122005 Anticancer combination therapy |
| 05/16/2013 | US20130121996 Novel Complex Mutations in the Epidermal Growth Factor Receptor Kinase Domain |
| 05/16/2013 | US20130121995 Compositions and Methods for Increasing Bone Mineralization |
| 05/16/2013 | US20130121994 Triazolopyridine derivatives |
| 05/16/2013 | US20130121986 Nitrogenated derivatives of pancratistatin |
| 05/16/2013 | US20130121985 Method and pharmacological composition for the diagnosis and treatment of male sub-fertility |
| 05/16/2013 | US20130121981 Vitamin C Composition for Use in the Prevention and Treatment of Stretch Marks, Radiation Dermatitis, and Other Skin Conditions and Methods of Using the Same |
| 05/16/2013 | US20130121974 Methods of making enhanced, autologous fat grafts |
| 05/16/2013 | US20130121969 Biodegradable polyurethane/urea compositions |
| 05/16/2013 | US20130121965 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent |
| 05/16/2013 | US20130121964 Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy |
| 05/16/2013 | US20130121963 N-phenyl-2-pyrimidineamine derivatives |
| 05/16/2013 | US20130121957 Hepatitis C Virus Inhibitors |
| 05/16/2013 | US20130121952 Hydrogel co-polymer composition and its uses, for example as a wound dressing |
| 05/16/2013 | US20130121930 Use of Glyceryl Trinitrate for Treating Hematomas |
| 05/16/2013 | US20130121923 Treatment of Male Sexual Dysfunction |
| 05/16/2013 | US20130121912 Microrna-198 as a tumor suppressor in pancreatic cancer |
| 05/16/2013 | CA2858372A1 Compositions and methods for the prevention of microbial infections |
| 05/16/2013 | CA2857953A1 An extended release formulation of a direct thrombin inhibitor |
| 05/16/2013 | CA2856235A1 Esters of dcpla and methods of treatment using the same |
| 05/16/2013 | CA2855932A1 Pkc activators and combinations thereof |
| 05/16/2013 | CA2855929A1 Pharmaceutical compositions and methods of use of 4-pregenen-11.beta.-17-21-triol-3,20-dione derivatives |
| 05/16/2013 | CA2855669A1 Compositions and methods for treating alzheimer's disease |
| 05/16/2013 | CA2855666A1 Combination of kinase inhibitors and uses thereof |
| 05/16/2013 | CA2855660A1 Therapeutic agent for arthrosis |
| 05/16/2013 | CA2855510A1 Nampt inhibitors |
| 05/16/2013 | CA2855390A1 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators |
| 05/16/2013 | CA2855372A1 Acc inhibitors and uses thereof |
| 05/16/2013 | CA2855362A1 Compounds for the modulation of beta-catenin expression and uses thereof |
| 05/16/2013 | CA2855290A1 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions |
| 05/16/2013 | CA2855249A1 Treatment of ovarian cancer with benzylidenebenzohydrazides |
| 05/16/2013 | CA2855245A1 Treatment of ovarian cancer with 2-amino-4h-naphtho[1,2-b]pyran-3-carbonitriles |
| 05/16/2013 | CA2855243A1 Method of treating a proliferative disease |
| 05/16/2013 | CA2855241A1 Compounds for the modulation of smn2 splicing |
| 05/16/2013 | CA2855211A1 N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
| 05/16/2013 | CA2855204A1 Pharmaceutical compounds |
| 05/16/2013 | CA2855180A1 Trolox derivative-modified fat-soluble anti-cancer pharmaceutical compounds, preparations, preparing methods and use thereof |
| 05/16/2013 | CA2855155A1 Treatment of hematologic malignancies with an anti-cxcr4 antibody |
| 05/16/2013 | CA2855022A1 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal |
| 05/16/2013 | CA2855005A1 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| 05/16/2013 | CA2855004A1 Nadph oxidase 4 inhibitors and use thereof |
| 05/16/2013 | CA2854935A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands |
| 05/16/2013 | CA2854932A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands |
| 05/16/2013 | CA2854879A1 Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
| 05/16/2013 | CA2854836A1 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction |
| 05/16/2013 | CA2854664A1 Method of quantifying cancer treatment |
| 05/16/2013 | CA2854631A1 Indolealkylamino-withasteroid conjugates and method of use |
| 05/16/2013 | CA2854622A1 Modulators of opioid receptors and methods of use thereof |
| 05/16/2013 | CA2854591A1 Process for the preparation of .beta.-c-aryl glucosides |
| 05/16/2013 | CA2854512A1 Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound |
| 05/16/2013 | CA2854424A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an so2-containing group as vanilloid receptor ligands |
| 05/16/2013 | CA2854372A1 Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging |
| 05/16/2013 | CA2854336A1 Dual inhibitor of met and vegf for treating cancer |
| 05/16/2013 | CA2854329A1 Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase |
| 05/16/2013 | CA2854264A1 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives |
| 05/16/2013 | CA2854186A1 Administration of a bis(thiohydrazide amide) compound for treating cancers |
| 05/16/2013 | CA2853872A1 Therapeutic combination of memantine and baclofen and pharmaceutical composition containing them |
| 05/16/2013 | CA2853833A1 Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto |
| 05/16/2013 | CA2853784A1 Treatment of blood lipid abnormalities and other conditions |
| 05/16/2013 | CA2853024A1 2-thiopyrimidinones |
| 05/16/2013 | CA2852991A1 Modulators of atp-binding cassette transporters |
| 05/16/2013 | CA2852820A1 Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a |
| 05/16/2013 | CA2852604A1 Inhibitors of phosphodiesterase type 10a |
| 05/16/2013 | CA2852127A1 Combination drug therapy for the treatment of solid tumors |
| 05/16/2013 | CA2850559A1 Combination therapy for ovarian cancer |
| 05/16/2013 | CA2850458A1 [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 |
| 05/16/2013 | CA2850448A1 Purine derivatives for the treatment of viral infections |
| 05/16/2013 | CA2849872A1 New cyclohexylamine derivatives having .beta.2 adrenergic agonist and m3 muscarinic antagonist activities |
| 05/16/2013 | CA2849868A1 New cyclohexylamine derivatives having .beta.2 adrenergic agonist and m3 muscarinic antagonist activities |
| 05/16/2013 | CA2849566A1 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| 05/16/2013 | CA2846568A1 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
| 05/15/2013 | EP2592155A2 EGFR mutations |
| 05/15/2013 | EP2592146A2 Methods and compositions for treating prostate cancer |
| 05/15/2013 | EP2592145A1 Medicament for the treatment of cardiac disease |
| 05/15/2013 | EP2592144A1 RNAI-mediated inhibition of Rho kinase 2 for treatment of ocular hypertension / glaucoma |
| 05/15/2013 | EP2592086A1 Telomerase inhibitors and a method for the preparation thereof |
| 05/15/2013 | EP2592083A1 Fused quinazoline derivatives and uses thereof |
| 05/15/2013 | EP2592082A1 Heteroaryl amide analogues as p2x7 antagonists |
| 05/15/2013 | EP2592081A1 Tetrahydrocarboline derivative |
| 05/15/2013 | EP2592080A1 Crystal of fused pyridine compound salt |
| 05/15/2013 | EP2592078A1 New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| 05/15/2013 | EP2592077A1 New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| 05/15/2013 | EP2592076A1 Substituted pyridine compound |
| 05/15/2013 | EP2592075A1 Pyridazine compounds for the treatment of inflammatory diseases |
| 05/15/2013 | EP2592073A2 Human protein tyrosine phosphatase inhibitors and their use |
| 05/15/2013 | EP2592072A2 Human protein tyrosine phosphatase inhibitors and their use |